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Abstract
Background: Hemophilia A (HA) is an X-linked recessive disorder caused by mutations in the Factor VIII (FVIII) gene
leading to deficient blood coagulation. As a monogenic disorder, HA is an ideal target for cell-based gene therapy,
but successful treatment has been hampered by insufficient engraftment of potential therapeutic cells.
Methods: In this study, we sought to determine whether co-transplantation of endothelial colony-forming cells
(ECFCs) and placenta-derived mesenchymal stromal cells (PMSCs) can achieve long-term engraftment and FVIII
expression. ECFCs and PMSCs were transduced with a B domain deleted factor VIII (BDD-FVIII) expressing lentiviral
vector and luciferase, green fluorescent protein or Td-Tomato containing lentiviral tracking vectors. They were
transplanted intramuscularly into neonatal or adult immunodeficient mice.
Results: In vivo bioluminescence imaging showed that the ECFC only and the co-transplantation groups but not the
PMSCs only group achieved long-term engraftment for at least 26 weeks, and the co-transplantation group showed a
higher engraftment than the ECFC only group at 16 and 20 weeks post-transplantation. In addition, cell transplantation
at the neonatal age achieved higher engraftment than at the adult age. Immunohistochemical analyses further showed
that the engrafted ECFCs expressed FVIII, maintained endothelial phenotype, and generated functional vasculature. Next,
co-transplantation of ECFCs and PMSCs into F8 knock-out HA mice reduced the blood loss volume from 562.13 ± 19.84 μl
to 155.78 ± 44.93 μl in a tail-clip assay.
Conclusions: This work demonstrated that co-transplantation of ECFCs with PMSCs at the neonatal age is a potential
strategy to achieve stable, long-term engraftment, and thus holds great promise for cell-based treatment of HA.
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Background
Hemophilia A (HA) is an X-link recessive coagulation
disorder caused by lack of coagulation factor VIII (FVIII)
with an incidence of 1 in 5000 male births [1]. Patients
with severe HA, defined as FVIII activity less than 1% of
normal, suffer from debilitating hemarthrosis,
life-threatening internal bleeding, and potentially fatal
intracranial hemorrhages [2]. Currently, the standard of
care for these patients is FVIII protein substitution ther-
apy (PST) with repeated intravenous injection of the
FVIII concentrates derived from human plasma or the
FVIII protein generated through recombinant DNA
technology [3, 4]. While this protein-based treatment
has greatly improved the quality of life and extended the
life expectancy of many HA patients, its high cost and
the need for lifelong infusion makes it far from an ideal
therapy [5]. Furthermore, patients under PST still experi-
enced bleeding episodes because of the fluctuation of
the infused proteins. Novel therapies to achieve sus-
tained FVIII expression in HA patients are needed to
overcome the serious limitations of current treatments.
As a monogenic disorder, HA is considered a highly
attractive target for gene therapy [6, 7], and even a 3–5%
increase in FVIII levels can substantially reduce symp-
toms and alleviate severe HA phenotype to moderate
HA phenotype [8]. A recent landmark clinical trial in
hemophilia A showed that an adeno-associated virus
serotype 5 (AAV5) vector-based gene therapy achieved
therapeutic levels of FVIII expression in the patients
over 1 year [9, 10]. But long-term effects of the
AAV-based gene therapy are yet to be determined. In
addition, about one third of HA patients are not suitable
candidates for this therapy because of their previous ex-
posure to AAV [11]. Ex vivo stem cell-based gene ther-
apy avoids direct administration of a large quantity of
the viral vector and circumvents the drawbacks of an
immune response to the viral vector. Since endothelial
cells (ECs) are the primary source of FVIII in the body
[12, 13], a number of studies have shown that ECs and
endothelial progenitor cells (EPCs) can correct the
phenotype in HA animal models [14–21]. However, pri-
mary ECs, such as liver sinusoidal ECs, are often limited
by their availability. Endothelial colony-forming cells
(ECFCs) are a subset of circulating EPCs in the periph-
eral or umbilical cord blood. Once isolated in culture,
ECFCs are highly proliferative and possess all phenotyp-
ical and functional characteristics of ECs [22], and sev-
eral studies have demonstrated their potential use in
cell-based therapies.
Mesenchymal stromal cells (MSCs) derived from adult
or perinatal tissues have been well established as a stem
cell therapy product for a wide variety of diseases and
conditions. Placenta-derived MSCs (PMSCs) represent
an emerging and exciting therapeutic agent for disease
treatment. The placenta is a unique, fetal-derived tissue
[23], and a number of studies including our own preclin-
ical research have shown that PMSCs can reliably be ob-
tained from early gestation placenta and used for the
treatment of developmental and perinatal diseases [24–
26]. These early gestation PMSCs display notable immu-
nomodulatory capabilities [27–29] and exhibit a greater
capacity to improve wound healing [30] and ex vivo ex-
pansion potential compared to term placenta or adult
bone marrow-derived mesenchymal stromal cells
(BM-MSCs) [28, 31]. PMSCs can also secrete a variety of
cytokines such as hepatocyte growth factor (HGF) and
vascular endothelial growth factor (VEGF) that are crit-
ical for endothelial cells growth and functional angiogen-
esis. The in vivo localization of PMSCs is yet to be
characterized. Whether all MSCs are pericytes that are
perivascular cells is still debatable. Nevertheless, peri-
cytes are important for endothelial cell protection and
functional structure formation [32, 33]. Even though
MSCs do not engraft long term after transplantation,
their various functions make them an ideal cell type for
co-transplantation applications [34–37]. It has been
demonstrated that when ECFCs are in contact with
MSCs, ECFCs secrete growth factors such as
platelet-derived growth factor-BB (PDGF-BB) and fibro-
blast growth factor 2 (FGF-2) that improve MSC prolif-
eration [38]. When ECFCs were co-transplanted with
BM-MSCs, the ECFC engraftment rate was improved by
interactions between ECFCs and MSCs through the
NOTCH signaling pathway [39].
The interaction between the transplanted cells and the
microenvironment at the site of transplantation can also
significantly influence cell fate and its engraftment po-
tential. To improve cell engraftment for the treatment of
HA, previous studies transplanted liver sinusoidal endo-
thelial cells (LSECs) to adult mouse models with liver
endothelium injured by use of toxins such as monocro-
taline (MCT) [18] or uPA [21] so that the transplanted
cells are exposed to an environment where ECs are
needed for the repair of endothelium. However, in clin-
ical situations, these invasive methods pose unnecessary
risks to patients and will not be feasible. Since the neo-
natal period is the fastest growing and developing period
of life, ECFCs transplanted during this period of time
could potentially be benefited from the developing niche
and contribute to vascular expansion [40]. Hence, appli-
cation of a cellular gene therapy to newborn HA patients
could rescue the phenotype before advancement of the
disease.
In this study, we intend to develop a novel cell-based
gene therapy for the treatment of HA by co-transplantation
of ECFCs and PMSCs. To achieve a high level of functional
FVIII secretion, ECFCs and PMSCs were both transduced
with a BDD-FVIII expressing lentiviral vector. We
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hypothesize that co-transplanting genetically modified
ECFCs with PMSCs will achieve stable long-term en-
graftment and provide a phenotypic correction of the
disease. We transplanted ECFCs and PMSCs alone or
in combination, into immune-deficient mice, and
compared their long-term cell engraftment. To iden-
tify the best age for the transplantation treatment, we
also compared the engraftment of ECFCs and PMSCs
in newborn and adult mice and assessed their engraft-
ment. Finally, we evaluated whether co-transplanting
genetically modified ECFCs with PMSCs alleviates the
symptom of HA in an animal model.
Methods
Cell isolation and expansion
Discarded term placenta was obtained from the Univer-
sity of California Medical Center, and ECFCs were iso-
lated from human umbilical cord blood as previously
described [41]. Mononuclear cells (MNCs) that were ob-
tained using Ficoll (GE Healthcare) gradient centrifuga-
tion were seeded onto rat-tail collagen type I (BD
Biosciences Discovery) coated tissue culture dishes and
cultured in Endothelial Cell Growth Medium MV-2
media (ECGM-MV2, PromoCell). ECFCs were used be-
tween passages 3 and 5 for all the experiments described
in this study.
PMSCs were isolated from discarded first-trimester
gestation placental tissue (gestation age of 11 weeks) col-
lected at the University of California, Davis Medical
Center, by using our established explant culture method
[29]. PMSCs were cultured in media consisting of
DMEM high glucose with 10% fetal bovine serum (FBS,
Hyclone), and 100 U/ml penicillin (ThermoFisher Scien-
tific) and 100 μg/ml streptomycin (ThermoFisher Scien-
tific). PMSCs were used between passages 4 and 7 in all
our experiments in this study.
Lentiviral vector transduction
All lentiviral constructs were generated at the UC Davis
Institute for Regenerative Cures (IRC) Vector Core.
ECFCs and PMSCs alone groups were transduced with
the pCCLc-MNDU3-LUC-PGK-EGFP-WPRE vector as
well as the pCCLc-MNDU3-BBD F8-PGK-NEO-WPRE
vector. To distinguish between ECFCs and PMSCs in
the co-transplantation group, a Td-Tomato containing
lentiviral vector pCCLc-MNDU3-F8-PGK-Tomato-WPRE
was used to label PMSCs in the group. Transductions
were performed in transduction media consisting of
DMEM high glucose, 10% FBS, and 8 μg/ml protamine
sulfate (MP Biomedicals) for 6 h. All vectors were trans-
duced at a multiplicity of infection (MOI) of 10. After that,
cells were cultured in ECGM-MV2 media for 72 h. After
72 h, cells were screened for neomycin resistance for 7
days cultured in media containing 2 μg/ml of G418 (EMD,
Millipore). Cells were then cultured and expanded in
ECGM-MV2 medium.
Flow cytometry
The surface markers of ECFCs and PMSCs were charac-
terized by flow cytometry. All antibodies were obtained
from BD Biosciences. ECFCs were stained with
APC-CD45 (560973), Alexa Fluor 647-CD31 (561654),
PE-CD34 (550761), APC-CD105 (562408), PE-CD144
(561714), PE-CD14 (561707), Alexa Fluor 647-CD309
(560495), and PE-CD146 (550315) while PMSCs were
stained with APC-CD29 (561794), FITC-CD44 (560977),
APC-CD73 (560847), FITC-CD31 (560984), FITC-CD90
(561969), FITC-CD34 (560942), APC-CD45 (560973),
and APC-CD105 (562408). APC-Ms IgG1 κ (550854),
FITC-Ms IgG2b κ (556655), FITC-Ms IgG1 κ (556650),
and Alexa Fluor 647-Ms IgG1 κ (557783) were used as
isotype controls, and anti-mouse Igκ CompBeads were
used to generate compensation controls. Transduction
efficiency was assessed by GFP or Td-Tomato expres-
sion. The Attune NxT Flow Cytometer (ThermoFisher
Scientific) was used for performing flow cytometry, and
FlowJo software (FlowJo LLC) was used for data
analyzing.
Acetylated low-density lipoprotein uptake
ECFCs were cultured in 0.5% BSA for 24 h and were
then incubated with 10 μg/ml Dil-AcLDL (Alfa Aesar) in
serum-free culture medium for 5 h at 37 °C. Cells were
then washed three times with PBS and fixed with 10%
formalin for 15 min and stained with DAPI (1:5000 in
water) to label the nuclei. The cells were imaged with a
Zeiss Observer Z1 microscope.
Tube formation assay
Twenty-four-well culture dishes were coated with 300 μl
Matrigel (BD Biosciences) per well and allowed to gel
for 60 min at 37 °C. 1 × 105 ECFCs were seeded onto the
Matrigel-coated wells and incubated at 37 °C, 5% CO2.
Phase contrast images were taken at 6 and 16 h after
seeding using Zeiss Observer Z1 microscope.
Enzyme-linked immunosorbent assay (ELISA)
ECFCs were seeded in a 6-well culture dish at 5 × 105
cells per well and cultured in 2 ml of ECGM-MV2 and
incubated at 37 °C, 5% CO2. After 48 h, we collected the
conditioned media and removed cell debris by centrifu-
gation at 1500 rpm for 10min. Quantification of FVIII
protein secreted by cells present in undiluted condi-
tioned media was assessed using FVIII ELISA kit (Affin-
ity Biologicals) as per the manufacturer’s instructions.
The standard was generated by human calibrator plasma
(Affinity Biologicals).
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Chromogenic assay
FVIII activity in undiluted conditioned media was pre-
pared as described above for FVIII ELISA which was
performed using Coamatic FVIII kit (Chromogenix) as
per the manufacturer’s instructions. The standard was
generated by coagulation reference calibration plasma
(Technoclone).
RT-PCR
Total RNA was extracted from cells or tissue using the
RNeasyPlus Mini kit (Qiagen), and cDNA was synthe-
sized using Superscript II Reverse transcriptase (Ther-
moFisher Scientific). We amplified target genes using
AccuPower PCR premix (Bioneer) at an annealing
temperature of 60 °C for 35 cycles, and products were
analyzed in a 2% agarose gel. The primer sequences of
human GAPDH and BDD-F8 are shown in Additional
file 1: Table S1.
In vivo cell transplantation
All animal procedures were approved by The University
of California, Davis (UCD) institutional animal care and
use committee (IACUC). All facilities used during the
study period were accredited by the Association for the
Assessment and Accreditation of Laboratory Animal
Care International (AAALAC). NSG (NOD/SCID/
IL2Rγ−/−) immunodeficient mice were purchased from
The Jackson Laboratory. Cells were resuspended in
16.7 μl ECGM-MV2 media and 3.3 μl of Matrigel (BD
Biosciences) and injected intramuscularly to the left hind
limb of each mouse. 3 × 105 GFP/LUC-labeled ECFCs or
PMSCs were used for ECFC only group and PMSC only
group, respectively. For the co-transplantation group,
3 × 105 GFP/LUC-labeled ECFCs and 2 × 105
Td-Tomato-labeled PMSCs were used. For the neonatal
group, cells were transplanted to mice at 3–5 days of
age, and for the adult group, cells were transplanted at
12 weeks of age.
To test the efficacy of the cells in the disease model of
HA, F8 mutant HA mice (B6;129S-F8tm1Kaz/J) were pur-
chased from The Jackson Laboratory. To avoid immune
rejection of the transplanted human cells in the im-
munocompetent HA mice, 210 mg/ml cyclosporine A
was added to the drinking water. 3 × 106 GFP/LUC-la-
beled ECFCs and 2 × 106 Td-Tomato-labeled MSCs were
suspended in 40 μl ECGM-MV2 media and 10 μl of
Matrigel and transplanted subcutaneously to both hind
limbs of each neonatal HA mouse at 2 weeks after birth.
This age falls within the realm of neonatal age of mice
and was necessary to properly perform the tail-clip
assay. To minimize the possibility of intramuscular
bleeding, a 28-G syringe was used for the subcutaneous
injection.
Bioluminescence imaging
Cells transplanted in the NSG mice were monitored via
In Vivo Imaging Spectrum (IVIS) system (PerkinElmer)
at designated time points. Animals were injected intra-
peritoneally with luciferase substrate D-luciferin (Gold
Biotechnology) at 100mg/kg body weight and main-
tained under anesthesia with 2% inhaled isoflurane for 5
min before imaging. The transplanted NSG mice were
imaged at the day of transplantation and weekly or
monthly thereafter up to 26 weeks after transplantation.
The HA mice were imaged 7 days after transplantation.
Images were analyzed by using Living Image®2.50 (Per-
kin Elmer). Total intensity was measured within a de-
fined area of the signal. Baseline intensity was
determined by using the same defined area where there
is no positive signal in the same animal.
In vitro co-culture of ECFCs and PMSCs
To study the effect of PMSCs on ECFCs, we designed
direct and indirect co-culture of these two cell types. For
direct co-culture, we combined 2.5 × 105 GFP-labeled
ECFCs with 2.5 × 105 PMSCs and seeded them in a
100-mm tissue culture treated dish. For indirect
co-culture, autoclaved silica gel that allowed media ex-
change was used to separate the ECFCs from PMSCs
seeding the same number as in direct co-culture. 0.25 ×
105 ECFCs were seeded for ECFC only group. After 24 h
of incubation in ECGM, we labeled proliferated cells
with bromodeoxyuridine (BrdU) by culturing cells in
5 μM BrdU for additional 24 h. Cell cycle measurements
were determined using the APC-conjugated BrdU Flor
Kit (BD Biosciences) according to the manufacturer’s in-
struction. BrdU, an analog of the DNA precursor thymi-
dine, can be incorporated into newly synthesized DNA
by cells entering and progressing through the S phase of
the cell cycle while 7-amino actinomycin D (7-AAD) is a
fluorescent intercalator that undergoes a spectral shift
upon association with DNA. With this combination,
two-color flow cytometric analysis permits the enumer-
ation and characterization of the cell cycle profile as well
as apoptosis. We analyzed the data by gating the
GFP-positive population to represent the ECFC.
To analyze the effect of PMSCs on ECFCs gene ex-
pression, 2.5 × 105 ECFCs were seeded onto a 100-mm
tissue culture treated dish overnight to allow them to at-
tach on the plate. PMSCs that were treated with an ir-
radiation dose of 10 Gy in order to inhibit proliferation
were then added to the dish. PMSCs were allowed to be
in contact with ECFCs for 0 min, 10 min, 6 h, and 24 h
time points. At each time point, both the adhered and
non-adhered cells were collected and total RNA was ex-
tracted using the RNeasyPlus Mini kit (Qiagen). Quanti-
tative real-time polymerase chain reaction (qPCR) was
performed by StepOnePlus real-time PCR system
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(Applied Biosystem, Waltham,MA) using SYBR Green
PCR master mix (ThermoFisher Scientific) at an anneal-
ing temperature of 60 °C for 40 cycles. The primer se-
quences used are listed in Additional file 1: Table S1.
Tail clip assay
A tail clip assay was performed to determine the blood
loss in HA mice with or without receiving ECFCs and
PMSCs. These mice were anesthetized using 2–3% iso-
flurane, and their tails were cut at 1.5 cm from the tip
with a surgical blade. Following 5 min of free bleeding,
pressure was applied to the cutting site for 1 min using a
hemostat. Blood was collected into EDTA-coated tubes
for 45 min after the cut. Coagulation efficacy was indi-
cated by the amount of blood collected.
Real-time PCR
To confirm the existence of human cells in the mouse
tissue after transplantation, muscle tissue was harvested
from animals that were sacrificed after IVIS imaging. A
cube of muscle tissue about 0.5 cm × 0.5 cm × 0.5 cm in
size with the strongest signal was collected from the site.
Total DNA from 30mg of homogenized tissue was ex-
tracted using DNeasy Blood & Tissue Kits (Qiagen).
qPCR was performed by using TaqMan fast universal
PCR master mix (ThermoFisher Scientific) at an anneal-
ing temperature of 60 °C for 40 cycles. The primer se-
quences used for human ERV3 and mouse GAPDH are
listed in Additional file 1: Table S1. A standard curve
was first generated for Ct value of each of the genes ver-
sus cell number. This curve was used to obtain the cell
number based on the gene expression in our experimen-
tal tissues.
Immunohistochemistry and immunocytochemistry
Muscle tissue samples that were obtained as described
above were fixed with 4% paraformaldehyde for 24 h,
protected by 30% sucrose dehydration for 48 h, and em-
bedded in the O.C.T compound (Sakura Finetek USA).
Serial sections were made at the thickness of 12 μm
using a Cryostat (Leica CM3050S) and collected onto
microscope slides (Matsunami Glass). Tissue sections
were extensively washed with PBS, blocked with 5% BSA
in PBS at room temperature for 1 h, and stained with
primary antibody at 4 °C overnight. The dilutions of pri-
mary antibodies were rabbit anti-human B2M (Dako)
1:400, rabbit anti-mouse CD31 (Dako) 1:20, rabbit
anti-SMA (Abcam) 1:50, goat anti-GFP (Novus Biologi-
cals) 1:100, and sheep anti-FVIII (Affinity Biologicals)
1:100. Sections were incubated with their respective sec-
ondary antibodies diluted at 1:500 for 1 h at room
temperature. The secondary antibodies were donkey
anti-rabbit conjugated with Alexa647 (ThermoFisher
Scientific), donkey anti-mouse conjugated with Alexa647
(ThermoFisher Scientific), donkey anti-goat (Thermo-
Fisher Scientific) conjugated with Alexa488, and donkey
anti-sheep conjugated with Alexa647 (ThermoFisher Sci-
entific). The slides were counterstained with 1:5000 dilu-
tion of DAPI for 5 min, mounted with Prolong Diamond
Antifade Mountant (Invitrogen), and imaged with a
Zeiss Observer Z1 microscope.
To investigate the morphology change of ECFCs
co-cultured with PMSCs, we seeded 1 × 104
GFP-transduced ECFCs and 1 × 104 Td-Tomato-trans-
duced PMSCs on Matrigel-coated 24-well plate and cul-
tured them in ECGM for 5 days. Cells were stained
using 1:400 diluted rabbit anti-VE-Cadherin (Cell Signal-
ing) or 1:40 diluted mouse anti-CD31 antibodies (Dako).
Statistics
Data are reported as mean ± standard deviation (SD) for
ELISA and chromogenic assay or mean ± standard error
of mean (SEM) for bioluminescence image and tail clip
assay. Statistical analysis of ELISA and chromogenic
assay was performed by Student’s t test. Bioluminescence
image analyses were performed using ANOVA with re-
peated measures. Tail clip assay analysis was performed
by one-way ANOVA. All statistical analyses were per-
formed using PRISM 7 (GraphPad Software Inc.), and
differences were considered significant when p < 0.05.
Results
Cell isolation, characterization, and transduction
ECFCs were isolated from human cord blood using our
previously established method [41]. The colonies formed
by proliferating cells appeared as early as the third day
of culture and gradually grew to confluency within 7–10
days of culture (Fig. 1A panels a, b). These cells showed
a typical cobblestone-like morphology (Fig. 1A panel c)
and their capability of acetylated low-density lipoprotein
uptake and tube formation (Fig. 1B, C). Phenotypes of
ECFCs were characterized by flow cytometry. They were
positive for surface markers CD31 (99.96%), CD105
(99.83%), CD146 (99.96%), CD144 (99.86%), and CD309
(79.45%) and negative for CD34 (2.17%), CD45 (0.98%),
and CD14 (0.27%) (Fig. 1D).
To overexpress FVIII in ECFCs, we transduced ECFCs
with two lentiviral vectors. One was pCCLc-
MNDU3-BDD-FVIII-PGK-NEO-WPRE encoding BDD-
F8. The other one was pCCLc-MNDU3-LUC-
PGK-EGFP-WPRE encoding luciferase and GFP for cell
tracking and engraftment analyses. Transduction rate was
96.5% according to flow cytometry analysis of the
GFP-positive cells (Fig. 1E). After viral transduction,
ECFCs maintained endothelial immunophenotype and
capability of acetylated low-density lipoprotein uptake and
tube formation (Additional file 1: Figure S1A-C). RT-PCR
analysis showed that BDD-F8 was highly expressed in the
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transduced ECFCs (ECFC-FVIII) but not in the
non-transduced ECFCs (Fig. 1F). ELISA was used to
measure the secreted amount of FVIII in the culture
medium using human calibrator plasma as the reference
standard. We found that the transduced ECFCs secreted
markedly higher levels of BDD-FVIII (17.8 ± 1.08%/106
cells) than the non-transduced cells (1.5 ± 0.12%/106 cells)
(Fig. 1G). The function of secreted BDD-FVIII was
assessed by coagulation chromogenic assay. FVIII activity
in the transduced cells (0.66 ± 0.13 IU/106cells) was sig-
nificantly higher than the non-transduced cells (0.09 ±
0.14 IU/106cells) (Fig. 1H).
PMSCs were isolated and characterized as previ-
ously described [26] and transduced with a lentiviral
vector pCCLc-MNDU3-F8-PGK-Tomato-WPRE. The
characterization of the transduced PMSCs and Td-Tomato
expression by flow cytometry are shown in Additional file 1:
Figure S2 A-B. The transduction rate was 87.53%.
In vivo engraftment of ECFCs and PMSCs in adult animals
To investigate cell survival and engraftment of trans-
planted cells in adult animals, GFP/luciferin-labeled
ECFCs (ECFC only group) or GFP/luciferin-labeled
PMSCs (PMSC only group) or a mixture of
Td-Tomato-labeled PMSCs plus GFP/luciferin-labeled
ECFCs (co-transplantation group) were intramuscularly
injected into the left hind limb of NSG mice at the adult
age of 12 weeks. Cell survival and engraftment were moni-
tored by IVIS. The bioluminescence signal in all the three
groups decreased considerably during the first 3 weeks
after transplantation. The signal in the PMSC only group
reached baseline at the third week of post-transplantation
and did not show any increase during the whole study
period of 24 weeks. In contrast, the ECFC-only group and
the ECFC/PMSC co-transplantation group also showed a
decrease in the signal intensity in the first 2 weeks of
post-transplantation but showed stable engraftment
higher than the baseline during the whole time period up
to 24 weeks of post-transplantation (Fig. 2).
In vivo engraftment of ECFC and PMSC in neonatal
animals
To investigate if the recipient age plays a role not only
in cell survival and engraftment but also in the
Fig. 1 Characterization of cord blood-derived ECFCs before and after transduction. (A) Representative phase contrast images of isolated
mononuclear cells from cord blood at day 3 (panel a) and day 7 (panel b) of in vitro culture. Typical cobblestone-like morphology of ECFCs at
passage 6 is shown in (panel c). (B) Acetylated low-density lipoprotein uptake by ECFCs. (C) Tube formation by ECFCs on Matrigel. (D, E) Flow
cytometric analyses of ECFC immunophenotype of surface markers (D) and GFP (E) expression after transduction (n = 1). Blue lines showed the
negative controls, red lines showed positive expressions respectively. (F) Transduced and non-transduced ECFCs were characterized for BDD-FVIII
gene expression by RT-PCR. (G) FVIII secretion detected by ELISA and (H) FVIII activity detected by chromogenic assay of ECFC culture media.
Data are expressed as mean ± SD. ****p < 0.0001, **p < 0.01, n = 3
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functional interaction between PMSCs and ECFCs, we
designed another study in which PMSCs only, ECFCs
only, or combination of ECFC and PMSC were trans-
planted by intramuscular injection into neonatal NSG
mice at 3–5 days of age. The same experimental setting
and numbers of cells were used in the neonatal mice as
in the adult mice. The animals were monitored for 26
weeks post-transplantation.
During the first 3 weeks of post-transplantation, the
IVIS signal decreased ten times every week in all groups,
indicating a decrease in cell survival during that period
(Additional file 1: Figure S3A). No significant difference
in cell retention among these three groups was detected
during these first 3 weeks after transplantation using re-
peated measurement data variance analysis (Additional
file 1: Figure S3B). The bioluminescence signal of the
PMSC-only group continuously decreased and reached
baseline after 12 weeks of transplantation (Fig. 3a top
panel). In contrast, the bioluminescence signal in the
ECFC-only group was maintained at the same intensity,
markedly higher than the baseline throughout the
26-week period (Fig. 3a middle panel). In the
co-transplantation group, the intensity was also
maintained from 4- to 26-week period with the highest
at the 20 weeks, suggesting long-term engraftment and
proliferation of the transplanted cells (Fig. 3a bottom
panel). The signal intensity was significantly higher in
both the ECFC-only and co-transplantation group com-
pared to the PMSC-only group. Further analysis of the
difference between the ECFC-only group and the
co-transplantation group, we performed Student’s t test
for each time point and found that at 16 weeks and 20
weeks, the co-transplantation group had a significantly
higher signal than ECFC-only group (p < 0.01 and p <
0.001) (Fig. 3b).
To quantitate the number of engrafted human cells in
these animals, we performed real-time PCR analysis of
the muscle tissues for human ERV3 expression and was
normalized to mouse GAPDH expression. We found
that 8.11 ± 4.93% (n = 3) of total number of cells are hu-
man cells in the co-transplanted group, while 1.50 ±
1.11% (n = 3) in the ECFC group. There was no detect-
able expression of human ERV3 in PMSC-only group (n
= 3) (Fig. 3c).
We compared cell engraftment between the same time
of mice that had been transplanted with ECFCs or
Fig. 2 Cell retention in adult NSG mice. Adult NSG mice were transplanted with ECFCs or PMSCs alone or in combination. a Representative
bioluminescence images of these mice in the indicated groups at different time points after cell transplantation. b The bioluminescence signals
in different groups of mice were quantitatively analyzed. Data were expressed as mean ± SEM. n = 4
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combination of ECFCs and PMSCs at either the neonatal
or the adult stage. In the period of 4 to 24 weeks of
post-transplantation, the neonatal transplanted group
had higher bioluminescence signal than the adult trans-
planted group in the co-transplanted group while in the
ECFC-only and PMSC-only group, there is no significant
difference (Fig. 3d). Our data suggest that performing
cell transplantation with the combination of ECFC and
PMSC in the neonatal period is superior to that in the
adult period for long-term cell engraftment.
Histological assessment of the transplanted cells
The mice that received cell transplantation at the neo-
natal stage were sacrificed at 26 weeks post-transplant-
ation, and the muscle tissues at the site of injection were
collected. Hematoxylin and eosin staining of these tis-
sues showed the tissue structure and located the trans-
planted cells (Fig. 4a, d, g). The transplanted
GFP-positive cells in the PMSC-only group were not de-
tected (Fig. 4b, c) and ECFC-only group were detected
under a fluorescence microscope (Fig. 4e, f ). In the
co-transplanted group, the GFP-positive ECFCs and
Td-Tomato-positive PMSCs were also detected in adja-
cent area (Fig. 4h, i).
Immunofluorescence staining was used for further
characterization of the transplanted cells in the
co-transplantation group. Human-specific beta-2 micro-
globulin (β2Μ) antibodies recognize a component of MHC
class I molecules in human cells. We confirmed that both
ECFCs and PMSCs expressed human β2M (Fig. 5a). Hu-
man CD31, an endothelial marker was present in ECFCs
but not in PMSCs (Fig. 5b). Our data suggested that the
transplanted ECFCs maintained their endothelial expres-
sion even at 26 weeks after transplantation.
Smooth muscle actin (SMA) expression was detected
in tube structures in the denser area of ECFCs but not
PMSCs, suggesting that ECFCs might be involved in the
formation of functional blood vessels while PMSCs
played a supporting function (Fig. 5c). In addition, both
ECFCs and PMSCs expressed the FVIII protein due to
Fig. 3 Long-term monitoring cell engraftment in mice transplanted at neonatal age. a Representative bioluminescence image of NSG mice
transplanted with ECFCs only, PMSCs only or ECFCs plus PMSCs at 3–5 days after birth over 26 weeks post-transplantation. b Quantitative analysis
of the bioluminescence signal intensity in these mice over time. c Real-time PCR analysis of different transplantation groups at 26 weeks post-
transplantation for the presence of human cells using human-specific ERV3 and mouse GAPDH primers. (D) Comparison of cell retention at 4 to
24 weeks of post-transplantation of mice between transplanted cells at the neonatal period and adult. Data were expressed as mean ± SEM. *p <
0.05, **p < 0.01, ##p < 0.01, ###p < 0.001. n = 5
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both cell types were transduced with the FVIII vector
(Fig. 5d).
EndMT occurred during co-culture of ECFCs and PMSCs
To investigate the mechanisms of how PMSCs help
ECFC engraftment, we performed cell cycle analysis
by labeling co-cultured ECFCs and PMSCs with BrdU
and 7-AAD. After 24 h of co-culture, the S phase
(BrdU incorporation) population in ECFCs alone was
84.3% but was decreased to 41.2% when ECFCs were
directly co-cultured with PMSCs and 27.8% when
they were indirectly co-cultured with PMSCs. At the
same time, the G0/G1 population in ECFCs alone was
9.8% but was increased to 44.2% in ECFCs when they
were directly co-cultured with PMSCs and 57.3%
when they were indirectly co-cultured with PMSCs.
(Fig. 6a). Our data show that PMSCs induced growth
arrest of ECFCs in vitro, regardless of direct or indir-
ect contact.
Endothelial-to-mesenchymal transition (EndMT) is
a process by which endothelial cells lose their
cell-specific markers and morphology and acquire a
mesenchymal cell-like phenotype [42]. Recently,
EndMT has been found to play a key role in the
early stages of angiogenesis [43]. We investigate
whether PMSCs promote EndMT in ECFCs. We
quantified the expression of two transcription fac-
tors Slug and Snail that are implicated in EndMT.
Both factors were activated in ECFCs after
co-cultured with PMSCs. Also, the expression of
α-SMA was upregulated, and expression of KDR
was downregulated implicating the loss of an EC
phenotype leading to a MSC-like phenotype (Fig.
6b). After 5 days of co-cultivation, a portion of the
ECFCs was no longer a cobblestone-like phenotype
and formed tubular structures with the help of
PMSCs (Fig. 6c pointed by the arrow). Therefore,
long-term co-culture is likely to ultimately contrib-
ute to angiogenesis. Immunocytochemical staining
indicated that some ECFCs lost the expression of
CD31 or VE-Cadherin (Fig. 6d pointed by the
arrow) after co-culture, demonstrating EndMT.
Fig. 4 a–i Cell engraftment in the transplanted sites at 26 weeks post-transplantation. Representative images of the mouse tissues at the site of
transplantation were collected based on their bioluminescence signal intensity. H&E stain is shown on the left panels. Fluorescence images are
shown on the middle and the right panels with different magnifications. ECFC only and PMSC only groups are GFP (green) positive. In the co-
transplanted group, ECFCs are GFP (green) positive and PMSCs are Td-Tomato (Red) positive
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Attenuation of the bleeding symptom of HA mice by co-
transplantation of ECFCs and PMSCs
In order to evaluate whether co-transplantation of ECFCs
and PMSCs has therapeutic effect on treating hemophilia
A, we subcutaneously transplanted 3 × 106 ECFCs and
2 × 106 PMSCs into the left and right hind limbs of each
neonatal HA mice at 2 weeks after birth. One week
post-transplantation, bioluminescence imaging showed
that the transplanted cells were retained in all five HA
mice (Fig. 7a). A tail clip assay was performed to detect
blood loss in these treated mice and was compared to
control non-treated HA mice and control normal C57BL/
6 mice. The blood loss volume in the control C57BL/6
mice and in the control HA mice was 131.5 ± 13.3 μl and
562.13 ± 19.84 μl, respectively (Fig. 7b). The blood loss
volume in the HA mice co-transplanted with ECFCs and
PMSCs was 155.78 ± 44.93 μl, which is similar to the nor-
mal C57BL/6 mice and is significantly less than that of the
control HA mice (Fig. 7b). RT-PCR analysis further con-
firmed the expression of F8 in the mouse tissues at the site
of injection, while the control HA mice had no detectable
expression of F8 (Fig. 7c). Our data demonstrated that
co-transplantation of ECFCs and PMSCs significantly at-
tenuated the bleeding symptom of HA mice.
Discussion
During the last decade, numerous attempts have been
made to develop a long-term cure for monogenic disor-
ders like hemophilia A. For hemophilia A treatment, in-
creasing circulating clotting FVIII level to above 1% of
Fig. 5 Characterization of the transplanted cells in the co-transplantation group. Representative immunohistochemistry staining images of the
mouse tissue at the site of injection in the co-transplanted group. a Both ECFCs and PMSCs expressed β2M (white). b CD31 staining (white) was
co-localized with ECFCs but not PMSCs. c SMA staining (white) was adjacent to ECFCs. d FVIII staining (white) was co-localized with ECFCs
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normal can significantly reduce risks of spontaneous in-
ternal bleeding [44]. The primary cellular source of FVIII
biosyntheses has been controversial for a long time.
Liver transplantation studies in the 1960s and 1980s
have shown that liver is the major source of FVIII [45,
46]. Although earlier evidence has suggested hepatocytes
to be the sole source of FVIII expression in the liver
[47], it was later proven to be primarily the LSECs [12,
13, 48]. In addition to liver, it was shown that endothelial
cells from other organs like lung, heart, intestine, and
skin also produce FVIII [49]. Therefore, using endothe-
lial cells seems to be a suitable candidate for
cell-mediated gene therapy for HA.
ECFCs are a group of cells with high proliferation cap-
acity. They are rare cells found at a concentration of
about 0.05–0.2 cells/ml in adult peripheral blood but are
highly abundant in human umbilical cord blood at a
concentration of about 2–5 cells/ml [50]. Numerous
studies have shown that ECFCs obtained from cord
blood are less mature with high proliferative potential in
vitro and in vivo than those obtained from adult bone
marrow [51]. Hence, cord blood could be a better source
of ECFCs than bone marrow. Consistent with previous
studies [52–54], we showed that the cord blood-derived
ECFCs expressed endothelial cell-surface antigens CD31,
CD105, CD144, CD146, and CD309 and did not express
the hematopoietic or monocyte cell surface antigens
CD14, CD45, or CD34. Their endothelial functional
phenotype was demonstrated by their ability to incorp-
orate Ac-LDL and to form tubes when seeded on matri-
gel. There is a controversy on whether EPC expresses
FVIII. Campioni et al. reported that EPCs from adult
peripheral blood express FVIII according to the ICC
staining [55]. However, Christian et al. reported that no
FVIII protein could be detected by Western blot in con-
centrated supernatants of un-transduced cord blood de-
rived endothelial cells (CBECs) [56]. The discrepancy
and inconsistency are likely due to different sources
and/or stages of EPCs/ECFCs (neonatal vs adult) were
assessed in these studies. In consistent with the latter re-
port, our data showed that cord blood-derived ECFCs
did not express an appreciable amount of FVIII. To in-
crease the amount of FVIII secretion, we transduced
these cells with lentivirus to overexpress FVIII.
To improve the engraftment of transplanted ECFCs,
co-transplantation of two or more types of cells has been
considered. Previous researches have shown that
co-transplantation of ECFCs with MSCs improves
vascularization and engraftment compared to ECFCs
alone. MSCs efficiently stabilized nascent blood vessels
in vivo by functioning as perivascular precursor cells
[57–59]. Co-transplantation of ECFCs and MSCs signifi-
cantly promote tissue recovery in cardiovascular disease,
cerebrovascular disease, and during bone regeneration
[60]. We are the first, to our knowledge, to investigate
co-transplantation of ECFCs and PMSCs to treat
hemophilia A. In our study, we found that ECFCs
showed persistent engraftment when transplanted alone
or along with PMSCs in immunodeficient mice. MSCs
significantly enhanced ECFCs engraftment at the later
time points of post-transplantation. Given the unique
immunomodulatory properties of PMSCs, we expect
that this co-transplantation strategy could yield even
more beneficial results in the immune competent clin-
ical setting. Importantly, significant attenuation of the
bleeding phenotype of the HA mice was achieved by
co-transplantation of ECFCs and PMSCs. However, we
Fig. 6 EndMT induced by co-culture ECFCs with PMSCs. a Cell
cycle analysis by flow cytometry of ECFCs direct or indirect co-
cultured with PMSCs. R1: S phase, R2: apoptotic, R3: G0/G1
phase, R4: G2+M phase. b Real-time PCR of EndMT-related gene.
Data are expressed as mean ± SD. ***p < 0.001, **p < 0.01, *p <
0.05, n = 3. c Cell phenotype of co-cultured ECFCs and PMSCs. d
Immunocytochemistry staining image of 5 days co-cultured
ECFCs and PMSCs
Gao et al. Stem Cell Research & Therapy           (2019) 10:34 Page 11 of 15
could not detect FVIII by ELISA in the blood collected
during the tail-clip assay. This might be due to the low
circulating levels of FVIII in the plasma in the trans-
planted HA mice. In addition, since ELISA was per-
formed to the blood samples collected during the
tail-clip assay, some circulating FVIII could have already
been consumed during coagulation at the site of the
wound. Future experiments will involve optimizing the
detection method of FVIII, improving approaches to in-
crease FVIII concentration in the blood, in addition to
using different sets of animals for the measurements of
plasma FVIII levels and for the tail clip assay.
The timing of the gene and cell therapy for an HA pa-
tient plays a significant role in determining outcomes.
Neonatal gene therapy is a promising strategy for treat-
ing multiple congenital diseases that can be diagnosed
shortly after birth. Therapeutic gene expression early in
life may prevent the development of irreversible damage
caused by the disease. In addition, introducing a
non-preexisting expression of the therapeutic protein
prior to maturation of immunity may enable immune
tolerance towards the therapeutic protein [61, 62]. This
is especially relevant to HA because about one third of
the HA patients that received FVIII replacement therapy
developed antibody inhibitors against FVIII. Our data
showed that cell transplantation at the neonatal stage
resulted in a higher level of engraftment compared to
cell transplantation at the adult stage. We demonstrated
further that co-transplantation of ECFCs with PMSCs
into the neonatal HA mice functionally alleviated their
bleeding symptom. Our study provides proof-of-concept
that neonatal cell-based gene therapy is effective and
preferable in treating hemophilia A.
The mechanism of interaction between PMSCs and
ECFCs during co-transplantation is not completely
understood. In our study, we showed that PMSCs in-
duced growth arrest of ECFCs in vitro and this might
potentially have an effect on the survival of the cells dur-
ing our co-transplantation studies. In addition, we found
that some of ECFCs developed EndMT after co-culture
with PMSCs, which is probably one of the mechanisms
by which MSCs increase the rate of ECFC colonization.
EndMT was originally discovered as an important mech-
anism of cardiac development [63] and has been widely
used in many studies to evaluate several systemic disease
processes such as fibrosis and tumors [64–66]. But re-
cent studies have shifted attention to the physiological
rather than pathological phenomena of this mechanism.
Previous reports have shown that vascular supporting
cells, such as pericytes and/or smooth muscle cells, may
be derived from endothelial cells themselves; therefore,
EndMT may be an important mechanism for recruiting
Fig. 7 Phenotype correction of hemophilia A mice by co-transplantation of ECFCs and PMSCs. a Bioluminescence images of the HA mice 7 days after
co-transplantation of ECFCs and PMSCs. b The volume of blood loss in a tail clip assay of C57BL/6 mice, HA mice, and the HA mice transplanted with
ECFCs and PMSCs. Data were expressed as mean ± standard error. n = 4 of the C57 group, n = 5 of treatment group, n = 3 of HA group. **p < 0.01. c
RT-PCR analysis of F8 expression in the limb tissues of HA mice and the HA mice transplanted with ECFCs and PMSCs
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such parietal cells during angiogenesis [43, 67]. EndMT
can be induced by fibroblast growth factor 1 (FGF-1) via
proteolytic matrix metalloproteinases 1 (MMP-1) activity
and plays a key role in early-stage angiogenesis [68].
EndMT has been reported to be an important mechan-
ism underlying neointimal formation in interpositional
vein graft via TGF-β–Smad2/3–Slug signaling pathway
[42]. These findings indicate that EndMT is likely to
have important implications for cell migration and ul-
timately function under physiological conditions.
PMSCs and ECFCs may interact with each other through
paracrine mechanism. Several studies have suggested para-
crine mechanism of MSCs in angiogenesis [69, 70].
NOTCH signaling was shown to contribute to mesenchy-
mal priming of ECFCs by stimulating a more differentiated
endothelial phenotype [39, 71, 72]. Interestingly, we found
that PMSCs survived persistently for more than 6months
when transplanted together with ECFCs, while the PMSCs
transplanted alone could rarely survive after 8 weeks
post-transplantation. It has been shown that ECFCs can
function as paracrine mediators to support MSCs by pro-
viding PDGF-BB, FGF-2, and other critical angiogenic fac-
tors [38, 73], that in turn promote the expansion of MSCs
and are essential for the proper functioning of various stem
cell niches [74–76]. But, these studies did not address the
long-term engraftment rate of the co-transplantation. Our
study suggests a mutually beneficial effect between ECFCs
and MSCs with respect to their long-term cell engraftment.
In summary, our study demonstrated that co-transplant-
ation of ECFCs with PMSCs at the neonatal age can
achieve stable, long-term engraftment. Therefore, the strat-
egy of co-transplantation of ECFCs with PMSCs holds great
promise for the treatment of HA.
Conclusions
HA is an ideal target for cell-based gene therapy, but
successful treatment has been hampered by insufficient
long-term engraftment of the therapeutic cells. We
co-transplanted PMSCs and ECFCs into neonatal NSG
mice which achieved a stable engraftment over 26 weeks
and reduced the blood loss volume of F8 knock-out mice
in a tail-clip assay. This work demonstrated that
co-transplantation of ECFCs with PMSCs at the neonatal
age is a potential strategy to achieve stable, long-term
engraftment, and thus holds great promise for cell-based
treatment of HA.
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